J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced ...

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

ASCO 2025 may be over, but the insights for the future of oncology are only just beginning. At the American Society of ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new ...

The CGM is based on magnetohydrodynamic (MHD) technology, which non-invasively samples interstitial fluid, the body fluid ...